

Interaction with patients and consumers


Overview of involvement in EMA activities during 2015

Nathalie Bere, Patients and Healthcare professionals Dept, Stakeholders and Communication Division






Interaction with patients: the EMA journey... so far



1




Patient and consumer involvement over the years..





Opportunities for involvement along the medicine lifecycle at EMA





Categories of patient participation:

Patients representing *patients'* organisations

- Management Board
- EMA Scientific Committee(s)


Patients representing *their* organisations

- Patients' and Consumers' Working Party (PCWP)
- EMA consultations
- Workshops

Patients as *individual* experts


- Scientific Advice / Protocol Assistance Procedures
- Scientific Advisory / ad hoc expert Groups
- Scientific committee consultations
- Review of documents






■MB/ Committee/WP members ■Individual experts ■Representatives of their organisations

Comparison of involvement across different activities



■2009 ■2010 ■2011 ■2012 ■2013 ■2014 ■2015





- Explore means to increase awareness on medicines evaluation
- Gather feedback and streamline provision of EMA training
- Conduct a reflection on providing further support to enable patient involvement
- Monitor and increase transparency on involvement of patients, consumers and organisations in EMA:
 - Establish system for regular collection of quantitative and qualitative data for monitoring and reporting purposes
 - Explore methodologies to measure the impact of patients' involvement on regulatory outcomes
 - Acknowledge and promote visibility of patient/consumer organisations input provided in Agency activities



Eligible organisations: patients/consumers





Patients representing patients' organisations

<u>Members of</u> :

- EMA Management Board (MB)
- Committee for Orphan medicines (COMP)
- Committee for paediatric medicines (PDCO)
- Committee for advanced therapies (CAT)
- Pharmacovigilance Risk Assessment Committee (PRAC)



Patients representing their organisations

EMA Working Party with Patients & Consumers Organisations (PCWP)

- 19 members and 16 alternates representing PCOs;
- 6 members from the EMA Scientific Committees;
- 1 member from the EMA secretariat;
- Observers from the CMD-h, HCPWP and MB.

Five PCWP meetings;

- one plenary meeting,
- two joint meetings with the HCPWP (including a dedicated session on "Biosimilars" and a workshop on "Risk minimisation tools")
- one with all eligible organisations
- one-day training session





Patients representing their organisations (Cont.)

Examples during 2015:

- Committee/EMA consultations
- Pharmacovigilance legislation forum
- Patient registries
- EMA policy on proactive publication of and access to clinical-trial data
- Pandemic preparedness
- WEB-RADR stakeholders survey
- Ad-hoc observers attending PCWP meetings
- Working groups
- Workshops

Patients also contribute to **EU-wide initiatives** where EMA is involved such as:

- Enpr-EMA European Network of Paediatric Research at the European Medicines Agency
- ENCePP European Network of Centres for Pharmacoepidemiology and Pharmacovigilance
- <u>WEB-RADR</u> Recognising Adverse Drug Reactions



Involvement in EMA workshops/conferences

- Workshop on biosimilars
- Science, Medicines, Health: Patients at the heart of future innovation conference
- Duchene (DMD) workshop
- Workshop on chordoma as a model for very rare cancers
- Webinar: Implementation of EMA policy on publication of clinical data
- EMA workshop on the development of new medicines for the treatment of ulcerative colitis and Crohn's disease
- Workshop on haemophilia registries
- Implement. policy on access to clinical data
- Follow-up stakeholder meeting on the implementation of EMA policy on publication of clinical data

- 9th Stakeholder Platform meeting
- Joint EFGCP-DIA-EMA paediatric conference
- Lunchtime talk and debate: 'Involving young people in the evaluation of medicines for children'
- EMA workshop on shortages
- Anticoagulants workshop
- Workshop to clarify concept/demonstrating of significant benefit of orphan medicines
- EMA 20th anniversary event: The view from the sharp end: what patients and healthcare professionals can do for us
- IMI ADVANCE project




Patients as individual experts

Medicines' development:


• Participation in scientific advice/protocol assistance procedures

Benefit/risk evaluations:

- Participation in scientific advisory / ad-hoc expert group meetings (SAGs) convened by CHMP or PRAC
- Respond to ad-hoc consultations on assessment of medicines from all Committees
- Review information on medicines: Package leaflets, EPAR summaries, safety communications (Q&As) and soon herbal summaries




Percentage of package leaflets and EPAR summaries reviewed






Feedback on comments received; EPAR summaries



62% of EPARs adjusted due to feedback by patients



- 1 What is ...
- 2 How is it used
- 3 How does it work
- 4 Benefits
- 5 Risks
- 6 Why is it introduced
- 7 Awaited info
- 8 Safety measures
- 9 Other info



Ongoing initiatives

- Pilot project to involve patients in CHMP plenary discussions
 - ➤ 3 cases so far; ongoing

• Elicitation of B/R preferences

- Pilot study with melanoma / myeloma patients
- Expanded study 2016

• Enhanced training materials

- 'EMA basics' short videos
- Info-sheets
- Improvements to webpages dedicated to patients

Topic groups

- Measure impact/value of patient involvement
- Acknowledge and promote visibility of patient input in the Agency's activities
- Training and support to patients
- Social media
- Involvement of young people



Continued to raise awareness

Participation in conferences

- EATG stakeholders meeting, Brussels
- Giving patients a voice Federal Joint Committee, Berlin
- PROTECT Final Symposium, EMA
- · Eurordis rare disease day media event
- LSE conference Pharmaceutical Policy: Pricing, access and reimbursement, London
- EFPIA 50 year anniversary of EU pharmaceutical legislation, Brussels
- Newcastle University Workshop: Participants not subjects – engaging patients and families in paediatric clinical research
- DIA Euromeeting-Paris
- Melanoma (MPNE) 2015 conference Brussels
- Myeloma Patients Europe annual meeting -Dubrovnik

- University of Copenhagen: Patient Involvement in medicines development and approvals
- · Eurordis summer school Barcelona
- EUPATI Advisory Board meeting Berlin
- CIRS patient Engagement workshop UK
- EUPATI training course for patients Barcelona
- WONCA conference Istanbul
- ISPOR roundtable Milan
- FT global pharmaceutical and Biotechnology conference London
- EUnetHTA-EMA meeting Copenhagen
- Invitation to participate and advise on workshop on stem cell therapies and gene therapies (Genetic Alliance UK/Wellcome Trust - Medical Research Council Cambridge Stem Cell Institute)
- Joint EMA-EBE (European Biopharmaceutical Enterprises) seminar



Conclusion

- The involvement of PCOs continues to be extremely beneficial;
- Patients are a recognised and integral part of the Agency's work with opportunities for input along the lifecycle of the medicines development
- With the passing years, their involvement not only expands, but <u>evolves</u> to ensure it occurs in the most optimal manner possible
- We will continue to look to enhance and improve involvement wherever feasible
- We look forward to a continued mutually beneficial collaboration during 2016!